OMER

+ Watchlist + Portfolio

Omeros Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $18.61
52-Week Range: $4.06 – $21.24
Market Cap: $1.37B
P/E (TTM): 15.47
EPS (TTM): 1.22
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: 0.81
Return on Equity: —
Return on Assets: -18.68%
Gross Margin: 38.34%
Operating Margin: 0.26%
Profit Margin: 324.88%
Current Ratio: 1.95
Debt/Equity: —
Total Debt: $296.87M
Free Cash Flow: $183.31M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.51B

OMER Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$112.72M	$114.87M	$119.52M	$81.30M
Selling, General & Admin	$50.67M	$49.66M	$47.43M	$41.50M
Operating Expenses	$163.39M	$164.53M	$166.95M	$122.80M
Operating Income	-$163.39M	-$164.53M	-$166.95M	-$122.80M
EBITDA	-$158.38M	-$143.16M	-$154.70M	-$121.83M
Pretax Income	-$182.03M	-$174.92M	-$180.32M	-$2.80M
Income Tax	$0.00	$0.00	$2.31M	$2.01M
Net Income	$47.42M	-$117.81M	-$156.81M	-$3.35M
Diluted EPS	0.76	-1.88	-2.70	-0.05
Diluted Shares	62.74M	62.74M	58.17M	63.51M

OMER Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.01M	$7.11M	$3.40M	$9.66M
Receivables	$242.02M	$37.47M	$36.82M	$36.27M
Current Assets	$443.24M	$217.90M	$134.12M	$215.67M
Total Assets	$590.97M	$378.27M	$277.08M	$325.63M
Current Liabilities	$136.38M	$53.32M	$79.53M	$78.06M
Long-Term Debt	$220.91M	$213.16M	$166.58M	$208.53M
Total Debt	$342.02M	$236.46M	$207.02M	$239.14M
Total Liabilities	$505.29M	$403.25M	$459.69M	$446.86M
Retained Earnings	-$635.72M	-$753.53M	-$910.35M	-$913.70M
Shareholders' Equity	$85.68M	-$24.98M	-$182.61M	-$121.23M
Working Capital	$306.85M	$164.58M	$54.59M	$137.60M
Net Debt	$304.28M	$206.05M	$184.18M	$215.94M

OMER Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$86.48M	$74.73M	-$148.80M	-$116.09M
Capital Expenditure	-$113.00K	-$426.00K	-$165.00K	-$65.00K
Free Cash Flow	-$86.60M	$74.30M	-$148.97M	-$116.16M
Depreciation & Amortisation	$952.00K	$920.00K	$950.00K	$964.00K
Stock-Based Compensation	$14.07M	$11.65M	$10.49M	$8.19M
Investing Cash Flow	-$127.56M	$27.45M	$82.22M	$164.52M
Financing Cash Flow	$124.25M	-$106.08M	$62.88M	-$42.17M
Share Repurchases	$0.00	-$4.65M	-$11.85M	$0.00
Net Change in Cash	-$89.80M	-$3.90M	-$3.71M	$6.26M

OMER Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$9.89M	$28.53M
Cost of Revenue	$0.00	$0.00	—	—	$587.00K	$798.00K
Gross Profit	$0.00	$0.00	—	—	$9.31M	$27.73M
Research & Development	$23.85M	$22.01M	$15.99M	$19.45M	$13.36M	$13.80M
Selling, General & Admin	$11.12M	$10.35M	$10.40M	$9.63M	$13.37M	$13.86M
Operating Expenses	$34.97M	$32.35M	$26.39M	$29.08M	$26.73M	$27.66M
Operating Income	-$34.97M	-$32.35M	-$26.39M	-$29.08M	-$17.42M	$74.00K
EBITDA	-$33.62M	-$25.67M	-$26.15M	-$28.85M	$57.44M	$14.44M
Pretax Income	-$37.56M	-$25.89M	-$21.24M	$81.90M	$51.31M	$6.67M
Income Tax	$0.00	$0.00	—	—	$57.00K	$29.00K
Net Income	-$33.46M	-$25.42M	-$30.92M	$86.45M	$56.06M	$13.23M
Diluted EPS	-0.58	-0.43	-0.47	0.98	0.62	0.15
Diluted Shares	58.06M	58.59M	66.26M	88.48M	90.12M	89.63M

OMER Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$4.26M	$1.90M	$2.40M	$9.66M	$1.91M	$1.99M
Receivables	$36.30M	$34.50M	$31.96M	$36.27M	$37.51M	$46.90M
Inventory	—	—	—	—	$183.00K	$842.00K
Current Assets	$96.18M	$69.65M	$71.81M	$215.67M	$180.35M	$185.24M
Total Assets	$235.16M	$200.57M	$185.71M	$325.63M	$286.17M	$286.83M
Current Liabilities	$83.22M	$85.50M	$80.76M	$78.06M	$59.44M	$94.96M
Long-Term Debt	$158.96M	$150.79M	$159.56M	$208.53M	$136.84M	$97.25M
Total Debt	$203.88M	$184.33M	$191.61M	$239.14M	$148.85M	$138.99M
Total Liabilities	$448.71M	$429.25M	$406.18M	$446.86M	$349.51M	$338.18M
Retained Earnings	-$943.80M	-$969.23M	-$1.00B	-$913.70M	-$857.63M	-$844.40M
Shareholders' Equity	-$213.55M	-$228.69M	-$220.48M	-$121.23M	-$63.33M	-$51.35M
Working Capital	$12.96M	-$15.86M	-$8.95M	$137.60M	$120.91M	$90.28M
Net Debt	$181.63M	$165.90M	$174.20M	$215.94M	$134.93M	$126.52M

OMER Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$35.84M	-$21.94M	-$18.47M	-$39.84M	-$14.51M	$4.15M
Capital Expenditure	-$41.00K	-$13.00K	-$11.00K	—	—	—
Free Cash Flow	-$35.88M	-$21.95M	-$18.48M	-$39.84M	-$14.51M	$4.10M
Depreciation & Amortisation	$289.00K	$200.00K	$240.00K	$235.00K	$239.00K	$193.00K
Stock-Based Compensation	$2.45M	$2.06M	$1.94M	$1.73M	$1.89M	$1.62M
Investing Cash Flow	$38.54M	$21.30M	-$6.86M	$111.55M	$28.73M	$3.40M
Financing Cash Flow	-$1.84M	-$1.72M	$25.82M	-$64.44M	-$21.98M	-$7.47M
Share Repurchases	$0.00	$0.00	$0.00	$0.00	-$4.15M	-$5.73M
Net Change in Cash	$861.00K	-$2.36M	$491.00K	$7.26M	-$7.75M	$82.00K

Market Snapshot

About

Omeros Corporation is a biopharmaceutical company focused on therapies targeting complement-mediated diseases and central nervous system disorders. The company's products and pipeline include treatments for surgical bleeding, renal disease, and neurological conditions. Omeros markets Omidria, an ophthalmic drug used during cataract surgery.